无容量
医学
内科学
化疗
危险系数
多西紫杉醇
肿瘤科
临床终点
不利影响
进行性疾病
胃肠病学
外科
作者
Morihito Okada,Ken Kato,Byoung Chul Cho,Masanobu Takahashi,Chen-Yuan Lin,Keisho Chin,Shigenori Kadowaki,Myung-Ju Ahn,Yasuo Hamamoto,Yuichiro Doki,Chueh-Chuan Yen,Yutaro Kubota,Sung-Bae Kim,Chih-Hung Hsu,Eva Holtved,Ioannis Xynos,Yasuhiro Matsumura,Akira Takazawa,Yuko Kitagawa
标识
DOI:10.1158/1078-0432.ccr-21-0985
摘要
Abstract Purpose: Limited long-term data are available on immune checkpoint inhibitor use in patients with advanced esophageal squamous cell carcinoma (ESCC). We report three-year follow-up data from our study of nivolumab versus chemotherapy (paclitaxel or docetaxel) in patients with previously treated ESCC. Experimental Design: ATTRACTION-3 was a randomized, multicenter, open-label, phase III trial. Overall survival (OS), time from randomization to death from any cause, was the primary endpoint. An exploratory subanalysis assessed OS according to the best overall response (BOR) with and without landmark at four months. Results: Of the enrolled patients, 210 received nivolumab and 209 received chemotherapy. With a minimum follow-up of 36.0 months, OS was longer in the nivolumab vs the chemotherapy group (median, 10.9 vs 8.5 months; hazard ratio, 0.79; p = 0.0264), with three-year OS rates of 15.3% and 8.7%, respectively. The median OS was longer with nivolumab vs chemotherapy irrespective of the BOR (complete response/partial response: 19.9 vs 15.4 months; stable disease: 17.4 vs 8.8 months, and progressive disease: 7.6 vs 4.2 months). Grade 3 or higher treatment-related adverse events were reported in 40 patients (19.1%) in the nivolumab group and 133 patients (63.9%) in the chemotherapy group. Conclusions: Nivolumab as second-line therapy demonstrated clinically meaningful long-term improvement in OS compared with chemotherapy in previously treated patients with advanced ESCC. The OS was consistently improved in the nivolumab group compared with the chemotherapy group regardless of BOR. Nivolumab was well tolerated over the three-year follow-up.
科研通智能强力驱动
Strongly Powered by AbleSci AI